Darren Charles Tomlinson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9161031/publications.pdf

Version: 2024-02-01

77 papers

3,576 citations

32 h-index 57 g-index

82 all docs 82 docs citations

times ranked

82

6117 citing authors

#	Article	IF	CITATIONS
1	Purification and Analysis of Circulating Lipid Particles. Methods in Molecular Biology, 2022, 2419, 193-212.	0.4	1
2	Affimer Tagged Cubosomes: Targeting of Carcinoembryonic Antigen Expressing Colorectal Cancer Cells Using <i>In Vitro</i> and <i>In Vivo</i> Models. ACS Applied Materials & Diterfaces, 2022, 14, 11078-11091.	4.0	41
3	Affinity purification of fibrinogen using an Affimer column. Biochimica Et Biophysica Acta - General Subjects, 2022, 1866, 130115.	1.1	O
4	One-step gold nanoparticle size-shift assay using synthetic binding proteins and dynamic light scattering. Sensors and Actuators B: Chemical, 2022, 361, 131709.	4.0	4
5	Protein-conjugated microbubbles for the selective targeting of S. aureus biofilms. Biofilm, 2022, 4, 100074.	1.5	5
6	Rapid Quantification of <i>C. difficile</i> Glutamate Dehydrogenase and Toxin B (TcdB) with a NanoBiT Split-Luciferase Assay. Analytical Chemistry, 2022, 94, 8156-8163.	3.2	6
7	Affimers and nanobodies as molecular probes and their applications in imaging. Journal of Cell Science, 2022, 135, .	1.2	4
8	Fibrinogen interaction with complement C3: a potential therapeutic target to reduce thrombosis risk. Haematologica, 2021, 106, 1616-1623.	1.7	9
9	Affimer-based impedimetric biosensors for fibroblast growth factor receptor 3 (FGFR3): a novel tool for detection and surveillance of recurrent bladder cancer. Sensors and Actuators B: Chemical, 2021, 326, 128829.	4.0	10
10	Selective Affimers Recognise the BCLâ€2 Family Proteins BCLâ€x _L and MCLâ€1 through Noncanonical Structural Motifs**. ChemBioChem, 2021, 22, 232-240.	1.3	9
11	Selection and characterisation of Affimers specific for CEA recognition. Scientific Reports, 2021, 11, 744.	1.6	11
12	Reagentless Affimer- and antibody-based impedimetric biosensors for CEA-detection using a novel non-conducting polymer. Biosensors and Bioelectronics, 2021, 178, 113013.	5.3	28
13	RAS-inhibiting biologics identify and probe druggable pockets including an SII-α3 allosteric site. Nature Communications, 2021, 12, 4045.	5.8	19
14	Piggybacking on the Cholera Toxin: Identification of a CTB-Binding Protein as an Approach for Targeted Delivery of Proteins to Motor Neurons. Bioconjugate Chemistry, 2021, 32, 2205-2212.	1.8	10
15	Isolation of Artificial Binding Proteins (Affimer Reagents) for Use in Molecular and Cellular Biology. Methods in Molecular Biology, 2021, 2247, 105-121.	0.4	7
16	Characterization and applications of a Crimean-Congo hemorrhagic fever virus nucleoprotein-specific Affimer: Inhibitory effects in viral replication and development of colorimetric diagnostic tests. PLoS Neglected Tropical Diseases, 2020, 14, e0008364.	1.3	4
17	Exploiting nanobodies and Affimers for superresolution imaging in light microscopy. Molecular Biology of the Cell, 2019, 30, 2737-2740.	0.9	36
18	Affimer–Enzyme–Inhibitor Switch Sensor for Rapid Wash-free Assays of Multimeric Proteins. ACS Sensors, 2019, 4, 3014-3022.	4.0	21

#	Article	IF	CITATIONS
19	Affimers as anti-idiotypic affinity reagents for pharmacokinetic analysis of biotherapeutics. BioTechniques, 2019, 67, 261-269.	0.8	10
20	Affimer reagents as tools in diagnosing plant virus diseases. Scientific Reports, 2019, 9, 7524.	1.6	10
21	Control of conformation in $\hat{I}\pm$ -helix mimicking aromatic oligoamide foldamers through interactions between adjacent side-chains. Organic and Biomolecular Chemistry, 2019, 17, 3861-3867.	1.5	11
22	Affimer proteins as a tool to modulate fibrinolysis, stabilize the blood clot, and reduce bleeding complications. Blood, 2019, 133, 1233-1244.	0.6	17
23	Sensitive and selective Affimer-functionalised interdigitated electrode-based capacitive biosensor for Her4 protein tumour biomarker detection. Biosensors and Bioelectronics, 2018, 108, 1-8.	5.3	57
24	Non-immunoglobulin scaffold proteins: Precision tools for studying protein-protein interactions in cancer. New Biotechnology, 2018, 45, 28-35.	2.4	20
25	Affimer proteins for F-actin: novel affinity reagents that label F-actin in live and fixed cells. Scientific Reports, 2018, 8, 6572.	1.6	38
26	Affimer proteins inhibit immune complex binding to Fcî ³ RIIIa with high specificity through competitive and allosteric modes of action. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E72-E81.	3.3	36
27	Ortsspezifische Funktionalisierung von Affimeren fù⁄4r die DNAâ€PAINTâ€Mikroskopie. Angewandte Chemie, 2018, 130, 11226-11230.	1.6	11
28	<i>FGFR3</i> mutation increases bladder tumourigenesis by suppressing acute inflammation. Journal of Pathology, 2018, 246, 331-343.	2.1	33
29	Siteâ€Specific Labeling of Affimers for DNAâ€PAINT Microscopy. Angewandte Chemie - International Edition, 2018, 57, 11060-11063.	7.2	71
30	Antibody Mimetics for the Detection of Small Organic Compounds Using a Quartz Crystal Microbalance. Analytical Chemistry, 2017, 89, 3051-3058.	3.2	20
31	Interfacing native and non-native peptides: using Affimers to recognise α-helix mimicking foldamers. Chemical Communications, 2017, 53, 2834-2837.	2,2	15
32	Ultraefficient Cap-Exchange Protocol To Compact Biofunctional Quantum Dots for Sensitive Ratiometric Biosensing and Cell Imaging. ACS Applied Materials & Samp; Interfaces, 2017, 9, 15232-15244.	4.0	34
33	Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk. Cardiovascular Diabetology, 2017, 16, 34.	2.7	95
34	Development of an Affimer-antibody combined immunological diagnosis kit for glypican-3. Scientific Reports, 2017, 7, 9608.	1.6	24
35	Alternative reagents to antibodies in imaging applications. Biophysical Reviews, 2017, 9, 299-308.	1.5	46
36	Ubiquitination of basal VEGFR2 regulates signal transduction and endothelial function. Biology Open, 2017, 6, 1404-1415.	0.6	15

#	Article	IF	CITATIONS
37	Generation of specific inhibitors of SUMO-1– and SUMO-2/3–mediated protein-protein interactions using Affimer (Adhiron) technology. Science Signaling, 2017, 10, .	1.6	44
38	Isolation of isoform-specific binding proteins (Affimers) by phage display using negative selection. Science Signaling, 2017, 10, .	1.6	26
39	Upregulated WEE1 protects endothelial cells of colorectal cancer liver metastases. Oncotarget, 2017, 8, 42288-42299.	0.8	7
40	Affimer proteins are versatile and renewable affinity reagents. ELife, 2017, 6, .	2.8	151
41	VEGF-A isoforms program differential VEGFR2 signal transduction, trafficking and proteolysis. Biology Open, 2016, 5, 571-583.	0.6	43
42	<scp>VEGFR2</scp> Trafficking, Signaling and Proteolysis is Regulated by the Ubiquitin Isopeptidase <scp>USP8</scp> . Traffic, 2016, 17, 53-65.	1.3	29
43	A place for precision medicine in bladder cancer: targeting the FGFRs. Future Oncology, 2016, 12, 2243-2263.	1.1	39
44	Label-free electrochemical impedance biosensor to detect human interleukin-8 in serum with sub-pg/ml sensitivity. Biosensors and Bioelectronics, 2016, 80, 607-613.	5. 3	111
45	Selective and Potent Proteomimetic Inhibitors of Intracellular Protein–Protein Interactions. Angewandte Chemie, 2015, 127, 3003-3008.	1.6	24
46	The cellular response to vascular endothelial growth factors requires co-ordinated signal transduction, trafficking and proteolysis. Bioscience Reports, 2015, 35, .	1.1	50
47	Development and characterisation of a 3D multi-cellular <i>in vitro</i> model of normal human breast: a tool for cancer initiation studies. Oncotarget, 2015, 6, 13731-13741.	0.8	26
48	Trivalent Gd-DOTA reagents for modification of proteins. RSC Advances, 2015, 5, 96194-96200.	1.7	9
49	Selective and Potent Proteomimetic Inhibitors of Intracellular Protein–Protein Interactions. Angewandte Chemie - International Edition, 2015, 54, 2960-2965.	7.2	82
50	An siRNA-based functional genomics screen for theÂidentification of regulators of ciliogenesis and ciliopathyÂgenes. Nature Cell Biology, 2015, 17, 1074-1087.	4.6	215
51	Exploration of the HIF-1 \hat{l} ±/p300 interface using peptide and Adhiron phage display technologies. Molecular BioSystems, 2015, 11, 2738-2749.	2.9	35
52	Vascular endothelial growth factors: multitasking functionality in metabolism, health and disease. Journal of Inherited Metabolic Disease, 2015, 38, 753-763.	1.7	44
53	Inhibition of complement C3 and fibrinogen interaction: a potential novel therapeutic target to reduce cardiovascular disease in diabetes. Lancet, The, 2015, 385, S57.	6.3	19
54	Phage display selected magnetite interacting Adhirons for shape controlled nanoparticle synthesis. Chemical Science, 2015, 6, 5586-5594.	3.7	32

#	Article	IF	Citations
55	Receptor tyrosine kinase structure and function in health and disease. AIMS Biophysics, 2015, 2, 476-502.	0.3	12
56	Vascular Endothelial Growth Factor A-Stimulated Signaling from Endosomes in Primary Endothelial Cells. Methods in Enzymology, 2014, 535, 265-292.	0.4	17
57	A High-Throughput Assay to Identify Modifiers of Premature Chromosome Condensation. Journal of Biomolecular Screening, 2014, 19, 176-183.	2.6	9
58	Adhiron: a stable and versatile peptide display scaffold for molecular recognition applications. Protein Engineering, Design and Selection, 2014, 27, 145-155.	1.0	136
59	High-Content, High-Throughput Screening for the Identification of Cytotoxic Compounds Based on Cell Morphology and Cell Proliferation Markers. PLoS ONE, 2014, 9, e88338.	1.1	51
60	Multidrug-resistant breast cancer: current perspectives. Breast Cancer: Targets and Therapy, 2014, 6, 1.	1.0	79
61	Proof of concept study to identify candidate biomarkers of fibrosis using high throughput peptide aptamer microarray and validate by enzyme linked immunosorbant assay. Journal of Biomedical Science and Engineering, 2013, 06, 32-42.	0.2	13
62	A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges. Advances in Urology, 2012, 2012, 1-10.	0.6	101
63	Mechanisms of FGFR3 actions in endocrine resistant breast cancer. International Journal of Cancer, 2012, 130, 2857-2866.	2.3	69
64	FGFR1-Induced Epithelial to Mesenchymal Transition through MAPK/PLCγ/COX-2-Mediated Mechanisms. PLoS ONE, 2012, 7, e38972.	1.1	82
65	Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. British Journal of Cancer, 2011, 104, 75-82.	2.9	157
66	Structureâ^'function studies of an engineered scaffold protein derived from Stefin A. II: Development and applications of the SQT variant. Protein Engineering, Design and Selection, 2011, 24, 751-763.	1.0	43
67	FGFR3 mutation affects cell growth, apoptosis and attachment in keratinocytes. Experimental Cell Research, 2010, 316, 2008-2016.	1.2	24
68	Altered Splicing of FGFR1 Is Associated with High Tumor Grade and Stage and Leads to Increased Sensitivity to FGF1 in Bladder Cancer. American Journal of Pathology, 2010, 177, 2379-2386.	1.9	57
69	Fibroblast Growth Factor Receptor 1 Promotes Proliferation and Survival via Activation of the Mitogen-Activated Protein Kinase Pathway in Bladder Cancer. Cancer Research, 2009, 69, 4613-4620.	0.4	111
70	Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner. Oncogene, 2009, 28, 4306-4316.	2.6	94
71	Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification. Oncogene, 2008, 27, 2716-2727.	2.6	73
72	Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene, 2007, 26, 5889-5899.	2.6	112

#	Article	IF	CITATIONS
73	FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene, 2005, 24, 5218-5225.	2.6	295
74	Alternative Splicing of Fibroblast Growth Factor Receptor 3 Produces a Secreted Isoform That Inhibits Fibroblast Growth Factor–Induced Proliferation and Is Repressed in Urothelial Carcinoma Cell Lines. Cancer Research, 2005, 65, 10441-10449.	0.4	64
75	Regulation of Fgf10 Gene Expression in the Prostate: Identification of Transforming Growth Factor- \hat{l}^21 and Promoter Elements. Endocrinology, 2004, 145, 1988-1995.	1.4	31
76	Differential Effects of Transforming Growth Factor- \hat{l}^21 on Cellular Proliferation in the Developing Prostate. Endocrinology, 2004, 145, 4292-4300.	1.4	31
77	Sonic hedgehog regulates prostatic growth and epithelial differentiation. Developmental Biology, 2003, 264, 352-362.	0.9	139